Better Patient Care Through Innovation

 

AVAILABLE NOW

Now available by prescription, SYNDROS® (dronabinol) oral solution is the first and only liquid dronabinol approved by the FDA.

Read More

About INSYS

Our vision is to improve the quality of patient care by building a specialty pharmaceutical company focused on cannabinoids and novel drug delivery systems that address unmet patient needs.

SCIENCE

We are an innovative organization with a focus on providing therapeutic solutions helping to improve the lives of patients. 

 

SCIENCE

We are an innovative organization with a focus on providing therapeutic solutions helping to improve the lives of patients. 

 

SOCIAL RESPONSIBILITY

Our commitment to better patient care is measured not only by our focus on bringing innovative technologies to patients and physicians, but also by the importance we place on making an impact within the communities where we work and live.

 

SOCIAL RESPONSIBILITY

Our commitment to better patient care is measured not only by our focus on bringing innovative technologies to patients and physicians, but also by the importance we place on making an impact within the communities where we work and live.

 

Recent News

INSYS Therapeutics Starts Proof-of-Concept Study of Epinephrine Nasal Spray for Anaphylaxis

Recent News

FDA Accepts New Drug Application (NDA) for Buprenorphine Sublingual Spray from INSYS Therapeutics

Recent News

INSYS Therapeutics, Inc. to Participate in the 29th Annual Piper Jaffray Healthcare Conference

Recent News

INSYS Therapeutics Starts Proof-of-Concept Study of Epinephrine Nasal Spray for Anaphylaxis

Recent News

FDA Accepts New Drug Application (NDA) for Buprenorphine Sublingual Spray from INSYS Therapeutics

Recent News

INSYS Therapeutics, Inc. to Participate in the 29th Annual Piper Jaffray Healthcare Conference